Amphotericin B liposomal - Gilead Sciences

Drug Profile

Amphotericin B liposomal - Gilead Sciences

Alternative Names: AmBisome; SM 26000; SM-26000 Injection; SMP 26000

Latest Information Update: 21 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; Sumitomo Dainippon Pharma
  • Class Antifungals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cryptococcosis; Febrile neutropenia; Fever of unknown origin; Mycoses; Visceral leishmaniasis
  • Discontinued Candidiasis; Histoplasmosis

Most Recent Events

  • 10 May 2018 Grupo Biotoscana enters into an agreement with Gilead Sciences to commercialise AMBISOME® in Peru, Paraguay and Bolivia
  • 30 Nov 2017 Gilead Science completes a phase-II/III clinical trials in Cryptococcosis in Tanzania, Zimbabwe, South Africa, Botswana (IV)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Candidiasis in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top